M. Sekiguchi

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603

Y. Sakata, Y. Komatsu, Y. Tsuji, 2022, The oncologist.

Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).

Y. Sakata, N. Sakamoto, Y. Komatsu, 2021 .

Indwelling catheters increase altered mental status and urinary tract infection risk: A retrospective Cohort Study

Y. Mio, A. Shiba, M. Sekiguchi, 2021, Annals of medicine and surgery.